[Evaluation of the treatment of cystic lymphangioma by percutaneous injection of Ethibloc in 20 patients].
BACKGROUND
Surgical treatment of cystic lymphangioma (CL) is so often followed by local and general complications that non invasive treatment must be considered.


METHODS
Between 1987 and 1993, 20 patients with a superficial macrocystic lymphangioma were treated by percutaneous injection of Ethibloc in order to reduce the volume of the CL, with a minimum follow-up of 1 year. Fourteen CL were cervico-facial and six were located in the upper half of the body. The size of the lesion was determined by echography: three CL were less than 5 cm in diameter, 12 between 5 and 10 cm, five more than 10 cm. Two to 5 mL of Ethibloc were injected during one (15 cases) or several sessions (five cases).


RESULTS
Reduction in volume was excellent in 12 patients after one session and in four patients after several sessions. Four patients had a poor result. All the patients suffered from an important inflammatory reaction for 2 or 3 days followed by exteriorisation of the Ethibloc in seven patients, with a discrete final scar.


CONCLUSIONS
These fair results suggest that intracystic injection of Ethibloc represents an effective alternative to surgery.
Martinot
V
V
Service de chirurgie plastique, hôpital Roger-Salengro, Lille, France.
Descamps
S
S
Février
P
P
Patenotre
P
P
Brevière
J M
JM
Piette
F
F
Pellerin
P
P
D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003973:Diatrizoate / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D005153:Facial Neoplasms / Q000188:drug therapy*; D005227:Fatty Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007249:Inflammation / Q000139:chemically induced; D007279:Injections, Subcutaneous; D018191:Lymphangioma, Cystic / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009333:Neck / Q000473:pathology; D011409:Propylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D012597:Sclerosing Solutions / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015028:Zein / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D012597:Sclerosing Solutions; D003973:Diatrizoate; D015028:Zein; C020481:alcoholic prolamine solution
Evaluation du traitement des lymphangiomes kystiques par injection percutanée d'Ethibloc chez 20 patients.